The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

The global tuna peptides market is undergoing a major transformation as industries and consumers alike embrace natural, sustainable, and high-performing ingredients. Valued at USD 973.4 million in ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Ro, the leading direct-to-patient healthcare company, was selected to present eight new research abstracts at ObesityWeek 2025, hosted by The Obesity Society in Atlanta, GA from November 4-7, 2025. Ro ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell rating is advised.

This focus on standardization is helping reduce integration complexity—an ongoing challenge for many healthcare organizations ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

In reviewing the current state of evidence, several points stand out. The strongest findings show that low doses of ketamine ...

A malaria test commonly used across Asia and South America “is not fit for purpose”, researchers have claimed.